Drug insight: Appetite suppressants

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 2, 2005, Pages 89-95

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Appetite suppressant; Cannabinoid receptor antagonists; Monoamine reuptake; Sibutramine; Sympathomimetic drug

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA INTERMEDIN; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; ANOREXIGENIC AGENT; BENZPHETAMINE; CANNABINOID RECEPTOR; CORTICOTROPIN[4-10]; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; LEPTIN; MAZINDOL; MELANIN CONCENTRATING HORMONE; MELANOCORTIN RECEPTOR; NEUROPEPTIDE Y; NORADRENALIN; PHENDIMETRAZINE; PHENTERMINE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; SEROTONIN; SEROTONIN RECEPTOR; SERTRALINE; SIBUTRAMINE; TOPIRAMATE; ZONISAMIDE;

AORTA VALVE REGURGITATION; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONSTIPATION; DEPRESSION; DIET; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; FATIGUE; FOOD INTAKE; HUMAN; INJECTION SITE REACTION; INSOMNIA; LANGUAGE DISABILITY; MEMORY DISORDER; NERVOUSNESS; NONHUMAN; OBESITY; PARESTHESIA; PHARMACOLOGICAL BLOCKING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION; XEROSTOMIA;

APPETITE DEPRESSANTS; EATING; ENTERIC NERVOUS SYSTEM; HUMANS;

EID: 20344378695     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0092     Document Type: Review

References (43)

1. Bray GA and Greenway FL (1999) Current and potential drugs for treatment of obesity. Endocr Rev 20: 805-875
2. Bray GA and Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404: 672-677
3. Kroeze WK et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsycopharmacology 28: 519-526
4. Sykas SL et al. (1983) Anorectic drugs which stimulate thermogenesis. Life Sci 33: 1269-1275
5. Lupien JR and Bray GB (1986) Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Pharmacol Biochem Behav 25: 733-738
6. Hansen DL et al. (1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68: 1180-1186
7. Scoville BA (1975) Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgments. In Obesity in Perspective. (Ed. Bray GA) Washington DC: Department of Health, Education, and Welfare Publication NIH 75-708, 441-443
8. Munro JF et al. (1968) Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1: 352-354
9. Haddock CK et al. (2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26: 262-273
10. Padwal R et al. (2003) Long-term pharmacotherapy for obsesity and overweight: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27: 1437-1446
11. Bray GA et al. (1999) Sibutramine produces dose-related weight loss. Obes Res 7: 189-198
12. James WPT et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM study group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119-2125
13. Wirth A and Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 1331-1339
14. McMahon FG et al. (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled multicenter trial. Arch Intern Med 160: 2185-2191
15. McMahon FG et al. (2002) Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16: 5-11
16. Hazenberg BP (2000) Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94: 152-158
17. Sramek, JJ et al. Efficacy and sefety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomized trial. J Hum Hypertens 16: 13-19
18. Wadden RA et al. (2001) Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.Arch Intern Med 161: 218-227
19. Ascher JA et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395-401
20. Anderson JW et al. (2002) Bupropion SR significantly enchances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10: 633-641
21. Guy-Grand B et al. (1989) International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142-1145
22. Weintraub M. et al. (1984) A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144: 1143-1148
23. Connolly HM et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588
24. Bray GA et al. (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11: 722-733
25. Wilding J et al. (2004) A randomized double-blind placebo-cotrolled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28: 1399-1410
26. Gadde KM et al. (2003) Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289: 1820-1825
27. Di Marzo V et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825
28. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285: 2486-2497
29. Cohen C et al. (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002 13: 451-463
30. Farooqi IS et al. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341: 879-884
31. Considine RV et al. (1995) Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 95: 2986-2988
32. Friedman JM (2002) The function of leptin in nutrition, weight, and physiology. Nutr Rev 60 (Part 2): S1-S14
33. Morton GJ and Schwartz MW (2001) The NPY/AgRP neuro and energy homeostasis. Int J Obes Relat Metab Disord 25 (Suppl 5): S56-62
34. Heymsfield SB et al. (1999) Recombination leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282: 1568-1575
35. Lambert PD et al. (2001) Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight again, even in leptin-resistant obesity. Proc Nat Acad Sci USA 98: 4652-4657
36. Ettinger MP et al. (2003) Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826-1832
37. Regeneron Pharmaceuticals (online 14 April 2003) Regeneron's AXOKINE® promotes weight loss in study of everweight and obese people with type 2 diabetes [http://www.regeneron.com/company/press_detail.asp?v_c_id=170] (accessed 23 December 2004
38. Palmiter RD et al. (1998) Life without neuropeptide Y. Recent Prog Horm Res 53: 163-199
39. Ludwig DS et al. (1998) Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am J Physiol 274 (Part 1): E627-E633
40. Ludwig DS et al. (2001) Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107: 379-386
41. Shimada M et al. (1998) Mice lacking melanin-concentrating hormone are hypohagic and lean. Nature 396: 670-674
42. Huszar D et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141
43. Fehm HL et al. (2001) The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 86: 1144-1148